Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Systemic lupus erythematosus (SLE) patients have a striking increase in cardiovascular (CV) comorbidity not fully explained by the Framingham risk score. Recent evidence from in vitro studies suggests that type I interferons (IFN) could promote premature CV disease (CVD) in SLE. We assessed the asso...

Full description

Bibliographic Details
Main Authors: Emily C Somers, Wenpu Zhao, Emily E Lewis, Lu Wang, Jeffrey J Wing, Baskaran Sundaram, Ella A Kazerooni, W Joseph McCune, Mariana J Kaplan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3351452?pdf=render